Abeona Therapeutics Inc. Common Stock

ABEONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
5.57 USD
↘ 0.02 (0.36%)AT CLOSE (11:59 AM EDT)
5.66
↗ 0.09 (1.67%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
5.66
↗ 0.09 (1.67%)
🔴Market: CLOSED

ABEO is currently priced at $5.57. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. ABEO is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Sep 18, 2026.

Open?$5.82
High?$5.84
Low?$5.53
Prev. Close?$5.59
Volume?2.8M
Avg. Volume?1.7M
VWAP?$5.61
Rel. Volume?1.63x
Bid / Ask
Bid?$5.57 × 100
Ask?$5.74 × 200
Spread?$0.17
Midpoint?$5.66
Valuation & Ratios
Market Cap?318.5M
Shares Out?57.2M
Float?47.4M
Float %?83.1%
P/E Ratio?N/A
P/B Ratio?2.49
EPS?-$1.10
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
226
Market Cap
318.5M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.abeonatherapeutics.com
Listed
1980-09-19
Address
6555 CARNEGIE AVE, 4TH FLOOR
CLEVELAND, OH 44103
Phone: 646-813-4701
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
52
Short Sent.?
25
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.82Distress
Confidence?62%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?31.99%Squeeze Risk
Short Interest?15.2M
Days to Cover?13.9
Free Float47.4M
Avg Daily Volume1.1M
Settlement Date2026-08-31
Financial Health
Current Ratio?6.63Strong
Quick Ratio?6.40Strong
Cash Ratio?2.27Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
64
2.49CHEAP▾
P/S?
Peers
100
S&P
3
12.48HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.4CHEAP▾
EV/Sales?
Peers
100
S&P
9
10.86HIGH▾
Returns & Efficiency
ROE?
S&P
3
-49.1%WEAK▾
ROA?
S&P
3
-35.0%WEAK▾
Cash Flow & Enterprise
FCF?$-81527000
Enterprise Value?$277.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist